Beware The Corrosive Consequences Of Indirect Costs

My baptism in the conflict between academic productivity and the acquisition of indirect costs occurred some years ago when my university unilaterally canceled a research grant made to my laboratory by the Rockefeller Foundation. The shock to my research program was hardly mollified by a vice president's explanation that the cancellation was necessary because the foundation had refused to pay indirect costs. The unpleasant possibility that the university administration might be more interested

Written byCarl Leopold
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

My baptism in the conflict between academic productivity and the acquisition of indirect costs occurred some years ago when my university unilaterally canceled a research grant made to my laboratory by the Rockefeller Foundation. The shock to my research program was hardly mollified by a vice president's explanation that the cancellation was necessary because the foundation had refused to pay indirect costs. The unpleasant possibility that the university administration might be more interested in collecting overhead dollars than in fostering academic productivity had not previously occurred to me.

My second lesson about the tension between productivity and indirect costs came when a senior administrator in my university recommended to the Office of Management and Budget that it would be better to decrease the numbers of research grants than to limit the amount of indirect costs permitted in federal grants. Now the battle lines became more visible. The university administration expressed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies